Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Allen Annis

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Clinical Investigation|May 1, 2026
Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapyJennifer Gherardini, Tara Samra, Tatiana Gomez-Gomez, et al.
Journal of Medicinal Chemistry|October 15, 2014
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinaseYongqi Deng, Gerald W Shipps, Alan Cooper, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical DevelopmentVincent Guerlavais, Tomi K Sawyer, Luis Carvajal, et al.
Scientific Reports|February 4, 2021
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastomaSarah E Woodfield, Yan Shi, Roma H Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Science Translational Medicine|April 13, 2018
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemiaLuis A Carvajal, Daniela Ben Neriah, Adrien Senecal, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Journal of Medicinal Chemistry|November 30, 2004
Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteasesCraig A Coburn, Shawn J Stachel, Yue-Ming Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignanciesDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Clinical Investigation|May 1, 2026
Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapyJennifer Gherardini, Tara Samra, Tatiana Gomez-Gomez, et al.
Journal of Medicinal Chemistry|October 15, 2014
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinaseYongqi Deng, Gerald W Shipps, Alan Cooper, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical DevelopmentVincent Guerlavais, Tomi K Sawyer, Luis Carvajal, et al.
Scientific Reports|February 4, 2021
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastomaSarah E Woodfield, Yan Shi, Roma H Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Science Translational Medicine|April 13, 2018
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemiaLuis A Carvajal, Daniela Ben Neriah, Adrien Senecal, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Journal of Medicinal Chemistry|November 30, 2004
Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteasesCraig A Coburn, Shawn J Stachel, Yue-Ming Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignanciesDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Pageof 2